A woman born without arms or legs on Monday won the right to have the class action she is leading against the firms behind thalidomide, a sedative blamed for birth defects, proceed in Australia.

A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report. Much like hydroxyurea, the only Food and Drug Administration-approved therapy for sickle cell, pomalidomide increases production of fetal hemoglobin which, unlike its adult counterpart, cannot take ...

A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report.

(Georgia Health Sciences University) A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report.

An Australian woman born without arms and legs will lead a mass lawsuit against the German and British firms behind thalidomide, a sedative blamed for birth defects, lawyers said Saturday.

In final draft guidance published today (17 June 2011) NICE recommends two treatments for multiple myeloma. Publication of this latest draft follows an appeal by the manufacturer of bortezomib, Janssen. The appeal panel met in November and upheld one of seven appeal points, stating that insufficient efforts had been made ...

Thalidomide may have been withdrawn in the early 1960s for use by pregnant women, but its dramatic effects remain memorable half a century later. Now, researchers have taken a major step toward understanding exactly how thalidomide causes the birth defects. This is important as thalidomide is still used to treat ...

Thalidomide may have been withdrawn in the early 1960s for use by pregnant women, but its dramatic effects remain memorable half a century later. Now, researchers have taken a major step toward understanding exactly how thalidomide causes the birth defects. This is important as thalidomide is still used to treat ...

(Federation of American Societies for Experimental Biology) Thalidomide may have been withdrawn in the early 1960s for use by pregnant women, but its dramatic effects remain memorable half a century later. Now, researchers have taken a major step toward understanding exactly how thalidomide causes the birth defects. This is important ...

Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma (HCC), according to data presented at the International Liver CongressTM 2011.1 A new study found thalidomide gave HCC patients who'd undergone grossly curative resection surgical removal of the cancerous part of the liver double the ...

Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma (HCC), according to data presented at the International Liver Congress 2011.1

Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma, according to data presented at the International Liver Congress 2011.